Bayer is trying to silence the critics of its blockbuster birth control pills Yaz and Yasmin by taking nay-sayers to court. But even in Europe where the laws don’t always guarantee free speech, Bayer is hardly getting a sympathetic ear.
“Should I still be on Yasmin?” asks Beth on a Drugs.com forum. The woman has been taking the popular birth control pills for two years and suddenly developed migraines with blurry vision. Soon after, she had knee surgery and developed a very large blood clot in her leg, called a deep vein thrombosis, or DVT. Doctors put her on the blood thinner coumadin and told her to continue taking Yasmin, but Beth is worried. “I’m swelled up like a balloon,” she writes. “Should I really still be on Yasmin?”
Sales of Yaz birth control pills fell 15 percent in the second quarter of 2010, which Bayer Corp. blames on increased competition from generics marketed in the United States by Teva Pharmaceutical Industries. Teva introduced its Yaz copycat, Gianvi, earlier this year only to be slapped with a patent lawsuit by Bayer. It’s not the first lawsuit Bayer has filed against Teva in hopes of protecting the multimillion dollar market share it has enjoyed with Yaz.
Bayer’s multimillion dollar birth control pill, Yaz, will go head-to-head with generic competition with the introduction of Teva Pharmaceutical Industries’ Gianvi. Teva was awarded a 180-day marketing exclusivity period for Gianvi by the Food and Drug Administration after being the first company to file an Abbreviated New Drug Application (ANDA). Bayer isn’t taking the news lightly. The company says it plans to sue Teva for prematurely launching the new “girl” on the block, which Bayer says they are not legally permitted to do until July 2011.
